Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns

NAActive, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 21, 2021

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2026

Conditions
Burns
Interventions
DEVICE

NovoSorb BTM

NovoSorb BTM comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a nonbiodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.

PROCEDURE

Standard of Care

Burn wounds will be treated using the institution's standard of care, e.g. primary skin grafting, cadaveric allograft followed by skin grafting.

Trial Locations (26)

10065

New York Presbyterian Weill Cornell Medicine, New York

18103

Lehigh Valley Hospital and Health Network, Allentown

19140

Temple University Hospital, Philadelphia

20010

MedStar Washington Hospital Center, Washington D.C.

23219

Virginia Commonwealth University Medical Center, Richmond

24157

Wake Forest Baptist Health, Winston-Salem

27599

University of North Carolina at Chapel Hill, Chapel Hill

30303

Emory University at Grady Memorial Hospital, Atlanta

33606

Tampa General Hospital, Tampa

43210

The Ohio State University/ Wexner Medical Center, Columbus

44308

Akron Children's Hospital, Burn Center, Akron

52242

University of Iowa Hospital and Clinics, Iowa City

53792

UW Health University Hospital, Madison

60153

Loyola University of Chicago, Maywood

66160

University of Kansas Hospital, Kansas City

70112

University Medical Center, New Orleans, New Orleans

75390

University of Texas Southwestern Medical Center, Dallas

85008

Valleywise Health, Phoenix

90033

Southern California Regional Burn Center at LAC+USC, Los Angeles

95817

University of California Davis Medical Center, Sacramento

06610

Bridgeport Hospital, Bridgeport

02115

Brigham and Women's Hospital, Boston

02446

Massachusetts General Hospital, Boston

Unknown

Bembde Hospital, Aurangabad

National Burns Centre, Mumbai

Ganga Medical Centre and Hospitals PVT Ltd, Coimbatore

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

PolyNovo Biomaterials Pty Ltd.

INDUSTRY

NCT04090424 - Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns | Biotech Hunter | Biotech Hunter